January 1, 1998American Journal of Respiratory and Critical Care Medicine

5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension

View Full Paper

Ask AI

Bookmark

Population

Lungs obtained from patients with primary pulmonary hypertension, patients with interstitial lung disease…

Design

Case-control

Authors

LWLaurel WrightUniversity of Minnesota RTRubin M. TuderTufts University JWJun WangSouth China Agricultural University

Discussion

Member takes

Implication

May implicate leukotriene pathways in PPH vasculopathy; hypothesis-generating for targeted inhibition trials.

Structured PICO

Population

Lungs obtained from patients with primary pulmonary hypertension (PPH), patients with interstitial lung disease (ILD), and normal control subjects.

Comparator

Lungs from patients with ILD and normal control subjects

Outcome

Localization and semi-quantitative abundance of 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP)surrogate

The overexpression of 5-LO and FLAP in the remodeled vessels of PPH lungs suggests that inflammation and leukotriene production may participate in PPH vasculopathy.

Cite This Study

Wright et al. (1998) studied this question.

synapsesocial.com/papers/6a7194fea528af2d65c4207b https://doi.org/10.1164/ajrccm.157.1.9704003

View Full Paper

Ask AI

Bookmark

5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider